Innovation
CEFObio is the progressive company with steady growth.
2020~2023
-
2023
05
Licensed by the Ministry of Food and Drug Safety for human cell management business/cell processing facility
04
Business agreement with Amicogen for human-derived cell culture elements(MOU)
03
Attracted Series D investment
02
Confirmed as a company specializing in materials, parts and equipment(Korea Planning & Evaluation Institute of Industrial Technology)
-
2022
11
Received award for contribution to commercialization of healthcare technology by Korea Health Industry Development Institute
11
Certified as an excellent company for job inventions by the Korea Invention Promotion Association
11
STeMiN®, a stem cell culture media cosmetics raw material, was selected as a ‘next-generation world-class product’
07
Designated as ararepharmaceuticals in development stage for femoral head osteonecrosis
07
Signed MOU for cell analysis research with ID-CELL FORENSICS Co., Ltd.
07
KU Institute of Convergence Science and Technology signed an MOU with StemExOne Co., Ltd. for joint development of stem cell and exosome therapyagent
03
Selected as a business operator in RFP6 and RFP8 by Korean Fund for Regenerative Medicine
-
2021
11
Kick-off meeting with Kyungpook National University Hospital for phase 1 clinical trial of CT01, a therapy agent for osteonecrosis of the femoral head
10
Introduced manufacturing method and usage technology of Natural killer cell (CAR-NK, NKT) from Korea Research Institute of Bioscience and Biotechnology (KR-10-2298640)
08
Acquired manufacturing license of advanced biopharmaceuticals
07
Attracted Series D investment
07
CT01, a therapy agent for femoral head osteonecrosis, obtained phase 1 clinical approval
-
2020
12
Submitted IND for femoral head osteonecrosis therapy agent CT01 to the Ministry of Food and Drug Safety and responded to the Ministry of Food and Drug Safety
10
Introduced manufacturing method and usage technology of Natural killer cell (NK Cell) from Korea Research Institute of Bioscience and Biotechnology (KR-10-2167548)
10
Registration of GMP factory
06
Factory validation completed until Phase III
05
Completed non-clinical efficacy test for CF-M801
03
Started manufacturing of Gwangmyeong GMP Center
Steady Growth
CEFObio is the progressive company with steady growth
2016~2019
-
2019
12
Started Phase l validation for Gwangmyeong GMP Center
09
Completed non-clinical safety test for CF-M801
04
Changed strategy for cell therapy agent (CF-M801)
-
2018
05
Completed patent registration for 3D stem cell osteogenic differentiation induction method using hydrogel (KR-10-1860301)
05
Attracted Series B investment
-
2017
08
Signed CDA for cell therapy development with Catapult Ltd., UK
06
Acquired ISO 9001 for enzymes and stem cell culture media (KS Q ISO9001:2015/ ISO9001:201)
02
Selected as a technology specialized company (ESP) by the Ministry of SMEs and Startups
-
2016
10
Completed patent registration for cell preservation compositions (KR 10-2014-0102083)
09
Signed MOU/CDA for clinical research on bone cell therapy agent with Kyungpook National University College of Medicine
08
Selected as a partner company of Korea Institute for Advancement of Technology (KIAT)
08
STeMiN™, a stem cell cosmetic culture medium composition, completed the registration of 4 patents (KR-10-1646236)
08
Signed MOU/CDA regarding bone cell therapy agent with McGil Univ, Canada
07
Signed MOU/CDA for development of horse cell therapy agent with the Animal and Plant Quarantine Agency and the Korea Racing Authority
Pioneering the future
CEFObio is a progressive company with steady growth.
2011~2015
-
2015
12
Selected as a creative convergence research project by the National Research Council of Science & Technology (Development of new drug evaluation technology based on 3D cell culture using reverse biotechnology techniques)
09
Selected as a technology commercialization project by the Ministry of Agriculture, Food and Rural Affairs (Development of bone cell therapy agent using mesenchymal stem cells derived from pet dog fat)
05
Selected as an industry-academic collaboration project by Catholic University (Development of enzymes and protocols optimized for 3D cell culture)
05
Selected as a family business by the Korea Institute of Science and Technology Information
03
Selected as a partner company by Korea Institute of Industrial Technology
-
2014
12
Selected as an R&D planning project by the Ministry of Agriculture, Food and Rural Affairs (Commercialization plan for development of bone cell therapy agent using mesenchymal stem cells derived from pet dog fat)
06
Completed patent registration for stem cell cryopreservation compositions (KR 10-1407355)
04
Selected as a ‘Brain Pool’ project hosted by the Korea Federation of Science & Technology Societies
-
2013
12
Selected as a start-up growth project by the Ministry of SMEs and Startups (Delopment of cell transplantation and culture kit using 3D gel)
12
Trademark registration ofCEFOgro (culture fluid) and STeMiN (cosmetics)
05
Selected as an R&D planning project by the Ministry of SMEs and Startups (3D gel for cell culture and transplantation)
-
2012
11
Signed an international joint research agreement with the University of Strathclyde, UK
09
Selected as an international joint research project by the Korea Institute for Advancement of Technology (KIAT) (Development of stem cell culture technology using Biogel)
03
Certified as a start-up business (Korea Technology Finance Corporation)
03
Registered as an embryo research institute (registration number 66)
02
Signed MOU with Scottish Biomedical
01
Establishment of CEFObio’s Institutional Bioethics Committee
01
Recognized as a corporate research institute (Recognition No. 2012110067)
-
2011
10
Establishment of CEFObio Co., Ltd.